Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis

Title: Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis
Authors: Stack, John R.; Madigan, Anne; Helbert, Laura; Dunne, Eimear; Gardiner, Elizabeth E.; Andrews, Robert K.; Finan, Roisin; Smyth, Elizabeth; Kenny, Dermot; McCarthy, Geraldine M.
Source: Stack, J R, Madigan, A, Helbert, L, Dunne, E, Gardiner, E E, Andrews, R K, Finan, R, Smyth, E, Kenny, D & McCarthy, G M 2017, 'Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis', PLoS ONE, vol. 12, no. 11, e0188027. https://doi.org/10.1371/journal.pone.0188027
Publication Year: 2017
Description: Objectives: Anti-citrullinated protein antibodies (ACPA) have been shown to cause platelet activation in vitro, through the low-affinity immunoglobulin G (IgG) receptor (FcγRIIa) on platelets. Platelet activation via engagement of FcγRIIa results in proteolytic cleavage and shedding of platelet specific glycoprotein VI (GPVI) which can be detected in the plasma as soluble GPVI (sGPVI). We hypothesized that plasma levels of sGPVI would be increased among patients with seropositive RA as a consequence of antibody-induced platelet activation and GPVI shedding. Methods: Samples from 84 patients with RA (65 seropositive and 19 seronegative) and 67 healthy controls were collected prospectively and analysed for sGPVI using a standardised ELISA. Results: Patients with seropositive RA had significantly higher levels of sGPVI compared to seronegative RA and controls. Median (IQR) sGPVI levels were 4.2 ng/ml (3.2, 8.0) in seropositve RA, 2.2 ng/ml (1.5, 3.5) in seronegative RA and 2.2 ng/ml (1.6, 3.4) in controls (p
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
ISSN: 1932-6203
Relation: info:eu-repo/semantics/altIdentifier/pmid/29141000; info:eu-repo/semantics/altIdentifier/wos/000415260400045; info:eu-repo/semantics/altIdentifier/pissn/1932-6203; info:eu-repo/semantics/altIdentifier/eissn/1932-6203
DOI: 10.1371/journal.pone.0188027
Availability: https://research.monash.edu/en/publications/6b414d69-dba0-41ab-bf81-a1f0e5ef09fc; https://doi.org/10.1371/journal.pone.0188027; https://researchmgt.monash.edu/ws/files/261902040/261901594_oa.pdf; https://www.scopus.com/pages/publications/85034064865
Rights: info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.A18318D2
Database: BASE